IDEXX Laboratories (NASDAQ:IDXX) had its price objective lifted by Piper Jaffray Companies to $211.00 in a report issued on Thursday, The Fly reports. The firm presently has an “overweight” rating on the stock. Piper Jaffray Companies’ price objective points to a potential upside of 8.79% from the company’s current price.
A number of other analysts have also weighed in on IDXX. Canaccord Genuity restated a “buy” rating and set a $180.00 price objective on shares of IDEXX Laboratories in a research note on Friday, October 6th. Zacks Investment Research lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, October 18th. Stifel Nicolaus restated a “buy” rating and set a $185.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, October 24th. Aegis restated a “sell” rating on shares of IDEXX Laboratories in a research note on Friday, December 8th. Finally, BidaskClub lowered shares of IDEXX Laboratories from a “hold” rating to a “sell” rating in a research note on Saturday, December 16th. Two research analysts have rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. IDEXX Laboratories has a consensus rating of “Buy” and an average price target of $183.29.
IDEXX Laboratories (NASDAQ IDXX) traded up $6.91 during trading hours on Thursday, reaching $193.95. 858,041 shares of the company’s stock were exchanged, compared to its average volume of 516,597. The company has a market cap of $16,274.14, a price-to-earnings ratio of 62.77, a P/E/G ratio of 2.07 and a beta of 0.42. The company has a debt-to-equity ratio of -12.48, a quick ratio of 0.77 and a current ratio of 0.95. IDEXX Laboratories has a 1-year low of $125.02 and a 1-year high of $198.73.
In other news, insider Giovani Twigge sold 2,000 shares of the firm’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $156.07, for a total transaction of $312,140.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Jonathan W. Ayers sold 18,000 shares of the firm’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $153.75, for a total transaction of $2,767,500.00. Following the sale, the chief executive officer now directly owns 1,064,573 shares in the company, valued at approximately $163,678,098.75. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 130,160 shares of company stock worth $20,019,685. Insiders own 2.77% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. National Asset Management Inc. boosted its holdings in shares of IDEXX Laboratories by 2.1% in the second quarter. National Asset Management Inc. now owns 2,051 shares of the company’s stock worth $332,000 after buying an additional 42 shares during the last quarter. QS Investors LLC boosted its holdings in shares of IDEXX Laboratories by 1.5% in the second quarter. QS Investors LLC now owns 4,068 shares of the company’s stock worth $657,000 after buying an additional 60 shares during the last quarter. Thrivent Financial For Lutherans boosted its holdings in shares of IDEXX Laboratories by 3.1% in the second quarter. Thrivent Financial For Lutherans now owns 3,340 shares of the company’s stock worth $539,000 after buying an additional 100 shares during the last quarter. LS Investment Advisors LLC lifted its holdings in IDEXX Laboratories by 8.2% during the third quarter. LS Investment Advisors LLC now owns 4,846 shares of the company’s stock valued at $754,000 after purchasing an additional 368 shares in the last quarter. Finally, Norinchukin Bank The lifted its holdings in IDEXX Laboratories by 6.2% during the third quarter. Norinchukin Bank The now owns 6,495 shares of the company’s stock valued at $1,010,000 after purchasing an additional 379 shares in the last quarter. 86.54% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “IDEXX Laboratories (IDXX) PT Raised to $211.00” was posted by American Market News and is owned by of American Market News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/02/01/idexx-laboratories-idxx-pt-raised-to-211-00.html.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
